Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer

Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer

“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.